Family: | State Street (SPDR) |
Name: | SPDR S&P Biotech ETF |
Inception Date: | 31-Jan-2006 |
Termination Date: | |
Investment Objective: | The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted. |
Prospectus | |
Top 10 Holdings | ||
VIKING THERAPEUTICS INC | VKTX | 1.1761% |
EXACT SCIENCES CORP | EXAS | 1.1284% |
CYTOKINETICS INC | CYTK | 1.1003% |
EXELIXIS INC | EXEL | 1.0883% |
MODERNA INC | MRNA | 1.0873% |
DYNE THERAPEUTICS INC | DYN | 1.0842% |
BRIDGEBIO PHARMA INC | BBIO | 1.0787% |
CRINETICS PHARMACEUTICALS IN | CRNX | 1.0643% |
SAREPTA THERAPEUTICS INC | SRPT | 1.0608% |
Top 10 Holdings Weight: | 10.9% |
Number of Holdings: | 140 |
Shares Outstanding: | 78,450,000 |
Total Net Assets: | 7,445,689,000 |
NAV: | 94.93 |
Net Expense Ratio: | 0.35% |
Asset Class: | Equities (Stocks) |
Developed or Emerging: | Developed Market Funds |
Country: | US |
Region: | |
Strategy: | |
Currency: | |
Commodity: | |
Sector: | Healthcare |
Industry: | Biotech |
Dividend Type: | |
Tax Exempt State: | |
Maturity Duration: | |
Market Cap: | Broad Market / Multi-Cap |
Credit Quality: | |
Mortgage Bond Types: | |
Bond Type: | |
Gov't Bond Types: | |
Reit Type: | |
Leverage Direction/Factor: | |
Is Currency Hedged: | No |
US or Ex-US: | Domestic |